Results 91 to 100 of about 543 (171)

Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose. [PDF]

Eur J Health Econ
Schweitzer MK, Dold MN, Genet A, Gossens K, Klein-Hessling T, Löffler N, Rabel M, Rasch A, Reuter EM, Schmelcher J, Wolfram N, Werner S.   +11 more
europepmc   +1 more source

Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting. [PDF]

J Pharm Policy Pract
d'Errico M, Giannarelli D, d'Angela D, Pinto C, Polistena B, Spandonaro F.   +5 more
europepmc   +1 more source

Onkologen sind für AMNOG-Evolution [PDF]

Im Focus Onkologie, 2012
openaire   +1 more source

OrthoRefine: automated enhancement of prior ortholog identification via synteny. [PDF]

BMC Bioinformatics
Ludwig J, Mrázek J.
europepmc   +1 more source

Pricing combination products: not how but who? [PDF]

Eur J Health Econ
Towse A, Briggs A, Steuten L.
europepmc   +1 more source

From evidence to care delivery: Opportunities and risks in health and science policy. A position paper of the Association of the Scientific Medical Societies in Germany (AWMF). [PDF]

Ger Med Sci
Wörmann B, Kopp I, Nothacker M, Klar E, Sedlmayr M, Vogeser M, Schliephake H, Treede RD.   +7 more
europepmc   +1 more source

A review of 25 years of National Institute of Health and Care Excellence decision making. [PDF]

J Comp Eff Res
Zhang X, Tikhonovsky N, Ramagopalan SV.
europepmc   +1 more source

Infografik: AMNOG [PDF]

Pro Generika e.V.
core   +1 more source

EU HTA Regulation and Joint Clinical Assessment-Threat or Opportunity? [PDF]

J Mark Access Health Policy
Schuster V.
europepmc   +1 more source